Regeneron's bone disease drug delivers in phase 2, poised for FDA filing

Regeneron's bone disease drug delivers in phase 2, poised for FDA filing

Source: 
Fierce Biotech
snippet: 

Regeneron’s rare disease drug outshone placebo in a phase 2 study, warding off the majority of new bone formation in adults with a disorder that causes the body’s soft tissues to turn into bone. Full results from the trial will form the backbone of the drug’s regulatory submission.